About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials in Atlanta | 372 Studies

Clinical Trials LymphomaAtlanta

Lymphoma Clinical Trials in Atlanta

Find 372 clinical trials for lymphoma near Atlanta, Georgia. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Atlanta

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 41-60 of 372 trials

CompletedCytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)The purpose of this trial is to evaluate a CMV vaccine given to related donor/recipient pairs (donors prior to peripheral blood stem cell donation and CMV-seropositive recipients…NCT00285259·Tucson, Arizona and 21 others Active not recruitingA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaB-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections).NCT05283720·Tucson, Arizona and 75 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

RecruitingInotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyThis phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute…NCT03959085·Birmingham, Alabama and 230 others

CompletedStudy of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid MalignanciesThe purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase…NCT00446342·Duarte, California and 5 others

CompletedStudy of Efficacy and Safety of CTL019 in Pediatric ALL PatientsThis is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.NCT02435849·Los Angeles, California and 22 others

CompletedAssessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients…NCT04105010·New Haven, Connecticut and 49 others

CompletedCarfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaThis phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma.NCT01336920·Atlanta, Georgia and 2 others

CompletedTacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaThis trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after…NCT00928018·Atlanta, Georgia and 4 others

CompletedStudy of the Glutaminase Inhibitor CB-839 in Hematological TumorsMany tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.NCT02071888·Scottsdale, Arizona and 6 others

CompletedLMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or LymphomaRATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal cells.NCT00085150·Atlanta, Georgia and 4 others

CompletedStudy of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaThis phase I clinical trial studies the side effects and the best dose of phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 when given together with rituximab in treating…NCT02049541·Atlanta, Georgia and 1 other

CompletedStudy of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaThe purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or…NCT00312845·Opelika, Alabama and 205 others

CompletedAMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/AttemptsThis study evaluates the safety, efficacy, and pharmacokinetics (PK) of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral…NCT00396331·Duarte, California and 7 others

CompletedTotal-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic CancerRATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells.NCT00044954·Denver, Colorado and 13 others

CompletedVELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell LymphomaThe purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell…NCT00085696·Los Angeles, California and 12 others

CompletedSafety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell LymphomaTo characterize safety, tolerability and to establish the maximum tolerated dose (MTD) of Tenalisib in combination with Romidepsin in patients with R/R T-cell lymphoma.NCT03770000·Los Angeles, California and 14 others

Active not recruitingValemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including…NCT04703192·Duarte, California and 59 others

CompletedClinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor…NCT03904134·Duarte, California and 51 others

RecruitingSynKIR-310 for Relapsed/Refractory B-NHLThis first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants…NCT06544265·Denver, Colorado and 4 others

CompletedComparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00059839·Birmingham, Alabama and 158 others

PreviousPage 3 of 19Next

Other Conditions in Atlanta

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia